Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Hypertriglyceridemia: HELP
N. Manamley
Based on 1 article published since 2009
(Why 1 article?)
||||
Expertise Level

  What is this?

Expertscape's algorithms degrade at low publication numbers. Thus, with only 1 published article on Hypertriglyceridemia from 2009 through 2019, it is not possible for Expertscape to reliably rate N. Manamley's expertise on this topic.

Work Locations
Details
Most likely:    Amgen      
2016
  • Amgen Inc., Thousand Oaks, CA, USA. · Amgen Ltd, Cambridge, UK. · Amgen Inc., Seattle, WA, USA. · Center for Metabolic Research, Veterans Administration San Diego Healthcare System, San Diego, CA, USA. · University of Texas Southwestern Medical Center, Dallas, TX, USA. · Pubmed 26434934
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here is the title of the one article written by N. Manamley in 2009-2019 about Hypertriglyceridemia:

  • AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. 2016
Show Full Article Record
Google Searches

Learn more about N. Manamley using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Amgen
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Amgen
2016
  • Amgen Inc., Thousand Oaks, CA, USA. · Amgen Ltd, Cambridge, UK. · Amgen Inc., Seattle, WA, USA. · Center for Metabolic Research, Veterans Administration San Diego Healthcare System, San Diego, CA, USA. · University of Texas Southwestern Medical Center, Dallas, TX, USA. · Pubmed 26434934
Yearly article counts 00010000000
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.